<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39258423</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-7278</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Environmental toxicology</Title><ISOAbbreviation>Environ Toxicol</ISOAbbreviation></Journal><ArticleTitle>SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11-MDM2-p53 Pathway in Glioma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/tox.24396</ELocationID><Abstract><AbstractText>Low expression of certain ribosomal proteins leads to the inactivation of p53, which is mediated mainly by RPL5 or RPL11 (ribosomal protein L11). It is also unknown what mechanisms drive aberrant ribosomal proteins expression in tumor. SRBD1 (S1 RNA-binding domain 1), as a highly conserved RNA-binding protein, is lowly expressed in glioma tissues and correlated with glioma prognosis. In this study, we observed that SRBD1 was closely related to p53 signaling. The upregulation of SRBD1 elevated p53 levels, thereby activating the p53 signaling pathway. As an RNA bind protein, SRBD1 could bind to the 5'-UTR of target genes and regulate RNA translation. We further conducted RNA immunoprecipitation using anti-SRDB1 antibody and noticed 29 hub RNA, including RPL11. RPL11 could inhibit MDM2-mediated p53 ubiquitination. SRBD1 upregulation promoted RPL11 binding to MDM2 via elevating RPL11 protein levels, which in turn activated the p53 signaling. Disrupting the p53 signaling blocked SRBD1-induced glioma suppression. In mouse xenograft model, SRBD1 ectopic expression was effective in reducing the total M2 tumor-associated macrophages (TAMs) density and suppressed glioma tumor growth. In summary, these data show that SRBD1 has a critical role in inhibition of glioma tumor growth and M2 macrophage polarization, and targeting RPL11-MDM2-p53 signaling may be an effective strategy to improve therapy and survival for glioma patients.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hongfu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0006-6807-207X</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Shuping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Rizhao Central Hospital, Rizhao, Shandong, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Manyi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yuechao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6389-4801</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Er</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9889-0723</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-8468-4942</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81802490</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>BK20231160</GrantID><Agency>Natural Science Foundation of Jiangsu Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Environ Toxicol</MedlineTA><NlmUniqueID>100885357</NlmUniqueID><ISSNLinking>1520-4081</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">M2 macrophage polarization</Keyword><Keyword MajorTopicYN="N">RPL11</Keyword><Keyword MajorTopicYN="N">SRBD1</Keyword><Keyword MajorTopicYN="N">cell cycle</Keyword><Keyword MajorTopicYN="N">glioma</Keyword><Keyword MajorTopicYN="N">p53</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39258423</ArticleId><ArticleId IdType="doi">10.1002/tox.24396</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Efeyan and M. Serrano, &#x201c;p53: Guardian of the Genome and Policeman of the Oncogenes,&#x201d; Cell Cycle 6, no. 9 (2007): 1006&#x2013;1010.</Citation></Reference><Reference><Citation>D. W. Meek and C. W. Anderson, &#x201c;Posttranslational Modification of p53: Cooperative Integrators of Function,&#x201d; Cold Spring Harbor Perspectives in Biology 1, no. 6 (2009): a000950.</Citation></Reference><Reference><Citation>I. Ringshausen, C. C. O'Shea, A. J. Finch, L. B. Swigart, and G. I. Evan, &#x201c;Mdm2 Is Critically and Continuously Required to Suppress Lethal p53 Activity in Vivo,&#x201d; Cancer Cell 10, no. 6 (2006): 501&#x2013;514.</Citation></Reference><Reference><Citation>M. de Oca, R. Luna, D. S. Wagner, and G. Lozano, &#x201c;Rescue of Early Embryonic Lethality in mdm2&#x2010;Deficient Mice by Deletion of p53,&#x201d; Nature 378, no. 6553 (1995): 203&#x2013;206.</Citation></Reference><Reference><Citation>S. N. Jones, A. E. Roe, L. A. Donehower, and A. Bradley, &#x201c;Rescue of Embryonic Lethality in Mdm2&#x2010;Deficient Mice by Absence of p53,&#x201d; Nature 378, no. 6553 (1995): 206&#x2013;208.</Citation></Reference><Reference><Citation>L. Daftuar, Y. Zhu, X. Jacq, and C. Prives, &#x201c;Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2&#x2010;p53&#x2010;MdmX Network,&#x201d; PLoS One 8, no. 7 (2013): e68667.</Citation></Reference><Reference><Citation>S. Bursa&#x107;, M. C. Brdov&#x10d;ak, M. Pfannkuchen, et al., &#x201c;Mutual Protection of Ribosomal Proteins L5 and L11 From Degradation Is Essential for p53 Activation Upon Ribosomal Biogenesis Stress,&#x201d; Proceedings of the National Academy of Sciences of the United States of America 109, no. 50 (2012): 20467&#x2013;20472.</Citation></Reference><Reference><Citation>M. S. Dai and H. Lu, &#x201c;Inhibition of MDM2&#x2010;Mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5,&#x201d; Journal of Biological Chemistry 279, no. 43 (2004): 44475&#x2013;44482.</Citation></Reference><Reference><Citation>M. A. Lohrum, R. L. Ludwig, M. H. Kubbutat, M. Hanlon, and K. H. Vousden, &#x201c;Regulation of HDM2 Activity by the Ribosomal Protein L11,&#x201d; Cancer Cell 3, no. 6 (2003): 577&#x2013;587.</Citation></Reference><Reference><Citation>L. Morgado&#x2010;Palacin, G. Varetti, S. Llanos, G. G&#xf3;mez&#x2010;L&#xf3;pez, D. Martinez, and M. Serrano, &#x201c;Partial Loss of Rpl11 in Adult Mice Recapitulates Diamond&#x2010;Blackfan Anemia and Promotes Lymphomagenesis,&#x201d; Cell Reports 13, no. 4 (2015): 712&#x2013;722.</Citation></Reference><Reference><Citation>S. Bursac, M. C. Brdovcak, G. Donati, and S. Volarevic, &#x201c;Activation of the Tumor Suppressor p53 Upon Impairment of Ribosome Biogenesis,&#x201d; Biochimica et Biophysica Acta 1842, no. 6 (2014): 817&#x2013;830.</Citation></Reference><Reference><Citation>E. Macias, A. Jin, C. Deisenroth, et al., &#x201c;An ARF&#x2010;Independent c&#x2010;MYC&#x2010;Activated Tumor Suppression Pathway Mediated by Ribosomal Protein&#x2010;Mdm2 Interaction,&#x201d; Cancer Cell 18, no. 3 (2010): 231&#x2013;243.</Citation></Reference><Reference><Citation>K. M. Goudarzi and M. S. Lindstr&#xf6;m, &#x201c;Role of Ribosomal Protein Mutations in Tumor Development (Review),&#x201d; International Journal of Oncology 48, no. 4 (2016): 1313&#x2013;1324.</Citation></Reference><Reference><Citation>A. R. Subramanian, &#x201c;Structure and Functions of Ribosomal Protein S1,&#x201d; Progress in Nucleic Acid Research and Molecular Biology 28 (1983): 101&#x2013;142.</Citation></Reference><Reference><Citation>N. Kanemaki, K. T. Tchedre, M. Imayasu, et al., &#x201c;Dogs and Humans Share a Common Susceptibility Gene SRBD1 for Glaucoma Risk,&#x201d; PLoS One 8, no. 9 (2013): e74372.</Citation></Reference><Reference><Citation>F. Mabuchi, Y. Sakurada, K. Kashiwagi, Z. Yamagata, H. Iijima, and S. Tsukahara, &#x201c;Association Between SRBD1 and ELOVL5 Gene Polymorphisms and Primary Open&#x2010;Angle Glaucoma,&#x201d; Investigative Ophthalmology &amp; Visual Science 52, no. 7 (2011): 4626&#x2013;4629.</Citation></Reference><Reference><Citation>Y. Zhang, H. Fan, C. Zou, et al., &#x201c;Screening Seven Hub Genes Associated With Prognosis and Immune Infiltration in Glioblastoma,&#x201d; Frontiers in Genetics 13 (2022): 924802.</Citation></Reference><Reference><Citation>L. Xu, H. Liu, J. Yu, et al., &#x201c;Methylation&#x2010;Induced Silencing of Maspin Contributes to the Proliferation of Human Glioma Cells,&#x201d; Oncology Reports 36, no. 1 (2016): 57&#x2013;64.</Citation></Reference><Reference><Citation>Y. Zhang, G. W. Wolf, K. Bhat, et al., &#x201c;Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53&#x2010;Dependent Ribosomal&#x2010;Stress Checkpoint Pathway,&#x201d; Molecular and Cellular Biology 23, no. 23 (2003): 8902&#x2013;8912.</Citation></Reference><Reference><Citation>S. Liu, N. R. Tackmann, J. Yang, and Y. Zhang, &#x201c;Disruption of the RP&#x2010;MDM2&#x2010;p53 Pathway Accelerates APC Loss&#x2010;Induced Colorectal Tumorigenesis,&#x201d; Oncogene 36, no. 10 (2017): 1374&#x2013;1383.</Citation></Reference><Reference><Citation>A. M. Carr, &#x201c;Cell Cycle. Piecing Together the p53 Puzzle,&#x201d; Science 287, no. 5459 (2000): 1765&#x2013;1766.</Citation></Reference><Reference><Citation>M. G. van Oijen and P. J. Slootweg, &#x201c;Gain&#x2010;of&#x2010;Function Mutations in the Tumor Suppressor Gene p53,&#x201d; Clinical Cancer Research 6, no. 6 (2000): 2138&#x2013;2145.</Citation></Reference><Reference><Citation>T. Zheng, J. Wang, Y. Zhao, et al., &#x201c;Spliced MDM2 Isoforms Promote Mutant p53 Accumulation and Gain&#x2010;of&#x2010;Function in Tumorigenesis,&#x201d; Nature Communications 4 (2013): 2996.</Citation></Reference><Reference><Citation>T. Zhang, G. Cheng, L. Deng, et al., &#x201c;Silence of S1 RNA Binding Domain 1 Represses Cell Growth and Promotes Apoptosis in Human Non&#x2010;Small Cell Lung Cancer Cells,&#x201d; Translational Lung Cancer Research 8, no. 6 (2019): 760&#x2013;774.</Citation></Reference><Reference><Citation>Y. Chen, X. Zhang, Q. Jiang, B. Wang, Y. Wang, and Y. Junrong, &#x201c;Lung Adenocarcinoma With a Novel SRBD1&#x2010;ALK Fusion Responding to Crizotinib,&#x201d; Lung Cancer 146 (2020): 370&#x2013;372.</Citation></Reference><Reference><Citation>S. J. Zheng, S. E. Lamhamedi&#x2010;Cherradi, P. Wang, L. Xu, and Y. H. Chen, &#x201c;Tumor Suppressor p53 Inhibits Autoimmune Inflammation and Macrophage Function,&#x201d; Diabetes 54, no. 5 (2005): 1423&#x2013;1428.</Citation></Reference><Reference><Citation>T. Cooks, C. C. Harris, and M. Oren, &#x201c;Caught in the Cross Fire: p53 in Inflammation,&#x201d; Carcinogenesis 35, no. 8 (2014): 1680&#x2013;1690.</Citation></Reference><Reference><Citation>A. Lujambio, L. Akkari, J. Simon, et al., &#x201c;Non&#x2010;Cell&#x2010;Autonomous Tumor Suppression by p53,&#x201d; Cell 153, no. 2 (2013): 449&#x2013;460.</Citation></Reference><Reference><Citation>L. Li, D. S. Ng, W. C. Mah, et al., &#x201c;A Unique Role for p53 in the Regulation of M2 Macrophage Polarization,&#x201d; Cell Death and Differentiation 22, no. 7 (2015): 1081&#x2013;1093.</Citation></Reference><Reference><Citation>X. Y. He, C. Xiang, C. X. Zhang, et al., &#x201c;p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors,&#x201d; Cell Reports 13, no. 5 (2015): 888&#x2013;897.</Citation></Reference><Reference><Citation>C. Garris and M. J. Pittet, &#x201c;Therapeutically Reeducating Macrophages to Treat GBM,&#x201d; Nature Medicine 19, no. 10 (2013): 1207&#x2013;1208.</Citation></Reference><Reference><Citation>B. Cardazzo, P. Hamel, W. Sakamoto, H. Wintz, and G. Dujardin, &#x201c;Isolation of an Arabidopsis thaliana cDNA by Complementation of a Yeast Abc1 Deletion Mutant Deficient in Complex III Respiratory Activity,&#x201d; Gene 221, no. 1 (1998): 117&#x2013;125.</Citation></Reference><Reference><Citation>N. Bonnefoy, M. Kermorgant, P. Brivet&#x2010;Chevillotte, and G. Dujardin, &#x201c;Cloning by Functional Complementation, and Inactivation, of the Schizosaccharomyces pombe Homologue of the Saccharomyces cerevisiae Gene ABC1,&#x201d; Molecular and General Genetics MGG 251, no. 2 (1996): 204&#x2013;210.</Citation></Reference><Reference><Citation>I. Bousquet, G. Dujardin, and P. P. Slonimski, &#x201c;ABC1, a Novel Yeast Nuclear Gene Has a Dual Function in Mitochondria: It Suppresses a Cytochrome b mRNA Translation Defect and Is Essential for the Electron Transfer in the Bc 1 Complex,&#x201d; European Molecular Biology Organization Journal 10, no. 8 (1991): 2023&#x2013;2031.</Citation></Reference><Reference><Citation>M. Iiizumi, H. Arakawa, T. Mori, A. Ando, and Y. Nakamura, &#x201c;Isolation of a Novel Gene, CABC1, Encoding a Mitochondrial Protein That Is Highly Homologous to Yeast Activity of bc1 Complex,&#x201d; Cancer Research 62, no. 5 (2002): 1246&#x2013;1250.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>